Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 9, 2012

PsiOxus Raises $34M to Take Oncolytic Virus Into Clinic

  • Technology commercialization and investment firm Imperial Innovations led a £22 million (about $34 million) funding round for PsiOxus Therapeutics. The financing will support Phase I and Phase II development of ColoAd1, PsiOxus’ chimeric oncolytic virus. The fundraising comprised £5.5 million each invested by Imperial Innovations and Invesco Perpetual, and new investors SR One and Lundbeckfond Ventures, who invested £11 million between them. Imperial Innovations now holds a 26% stake in PsiOxus.

    PsiOxus Therapeutics was formed in 2010 through the merger of Imperial College, London spin-out Myotec Therapeutics, and Hybrid Biosystems, which originally developed the adenovirus-based ColoAd1 in collaboration with Bayer Schering. The broad-spectrum oncolytic virus has been developed using evolutionary approaches, and will initially be developed for the treatment of metastatic colorectal cancer and primary hepatocellular carcinoma. Last September PsiOxus received a Translation Award from the Wellcome Trust worth up to £1.8 million to support clinical development of the viral vaccine candidate.

    PsiOxus’ lead clinical-stage candidate, MT-102, was originally developed by Myotec. The small molecule drug is an anabolic catabolic transforming agent (ACTA) in Phase II development for treating cancer therapy-related cachexia and sarcopenia.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »